Recent Asset Sale BioReference Laboratories recently sold its cancer testing assets to LabCorp for $192 million, indicating a strategic focus that may open opportunities for suppliers or partners interested in other specialized testing areas or complementary services to support their ongoing operations.

Expansion Through Partnerships The company's collaboration with Prognos Health and Teladoc Health highlights a commitment to advancing precision medicine and telehealth solutions, presenting opportunities to offer innovative diagnostic tools, digital health integrations, or remote testing services.

Focus on Oncology The launch of OnkoSight AdvancedTM for tumor DNA profiling demonstrates a strong emphasis on oncology diagnostics, creating potential sales avenues for specialized testing reagents, laboratory equipment, and next-generation sequencing technologies tailored for cancer research and treatment.

Workforce Adjustments Recent layoffs at the Elmwood Park location suggest ongoing operational shifts, which may be leveraged to offer workforce management solutions, onboarding services, or technology upgrades to improve efficiency during restructuring phases.

Market Positioning With an estimated revenue between $100M and $250M and a focus on innovative laboratory testing, BioReference presents opportunities for partners with scalable testing solutions, lab automation technologies, or niche diagnostic services aligned with their strategic growth and patient-centric offerings.